Get Your OTC Drug to Market in Canada and the US — Without Guessing Your Pathway

We support companies developing, licensing, importing, or marketing over-the-counter (OTC) drug products in Canada and the United States. Our focus is regulatory defensibility — aligned with monographs, labelling requirements, and long-term compliance expectations.

Book an OTC Strategy Call

What Skipping the Right Pathway Actually Costs

Your US Product Doesn't Transfer

Canada has its own review process for every product. Health Canada may apply different monograph standards, ingredient limits, or concentration thresholds than the FDA — and your US label will not meet Canadian requirements as-is.

No DIN Means No Legal Sale

Selling an OTC drug in Canada without a Drug Identification Number is not permitted. Health Canada uses the DIN system to track every approved product and enforce against products that lack one.

Wrong Pathway Resets Your Clock

Submitting as a monograph product when your formulation doesn't actually align sends you back to square one — with months of delay and the evidence package you should have built from the start.

Canada — Health Canada

Monograph vs. Non-Monograph: Which Pathway Applies to You?

The single biggest factor in how fast your OTC product reaches market is whether it aligns with an existing Health Canada monograph or requires a non-monograph submission. Getting this classification right before you submit is the difference between a roughly 90-day review and a process that can run significantly longer.

Faster Pathway

Monograph-Aligned OTC

If your product matches an existing Health Canada monograph — common categories include sunscreens, antacids, and antifungals — your DIN application generally moves faster, with Health Canada targeting approximately 90 days for review.

Ingredients, concentrations, and indications align with the published monograph
Pre-cleared safety and efficacy data reduces your evidence burden
Faster, more predictable review timeline

We confirm true monograph alignment before you submit — partial alignment is treated as non-monograph and loses the speed advantage entirely.

Full Submission

Non-Monograph OTC

If your formulation, indication, or combination of ingredients doesn't match an existing monograph, you'll need a non-monograph submission with additional supporting evidence — extending your review period beyond the standard monograph timeline.

Requires a more complete safety and efficacy evidence package
Common for novel formulations, new indications, or unusual ingredient combinations
Longer, less predictable review timeline — planning ahead matters most here

We build the evidence package strategically so you're not submitting more than necessary, while still meeting Health Canada's bar.

Canada – Health Canada OTC Drugs

Product classification & pathway assessment
Monograph alignment (ingredients, indications, directions)
DIN readiness & submission support
Label compliance review (Drug Facts / Canadian requirements)
GMP / site licensing considerations where required
Post-market compliance & change management

USA – U.S. FDA OTC Framework

OTC monograph pathway guidance
Label & claims review, risk-focused and practical
Facility & listing readiness direction
Regulatory documentation support for launch teams
Quality/compliance coordination with manufacturers
Change control support for formulation, claims, and packaging

What You Get

Clear pathway recommendation — what applies and what doesn't
Label/claims risk notes tied to actual requirements, not generic opinions
Actionable next steps with timelines and responsibilities
Submission / readiness support where needed

Who We Work With

OTC brand owners & marketers
Contract manufacturers
Importers & distributors
International companies entering Canada/USA

Expert Answers to Common Regulatory Questions

Frequently Asked Questions (OTC Drugs)

What's the difference between a DIN and an NPN?

A DIN (Drug Identification Number) is issued for conventional OTC drugs, while an NPN (Natural Product Number) is issued for natural health products. The two pathways have different evidence requirements and different regulatory frameworks — we assess which one actually applies to your product before you submit anything.

Can I sell my US-approved OTC product in Canada as-is?

No. Canada has its own review process, and Health Canada may apply different monograph standards, ingredient restrictions, or concentration limits than the FDA. Your US label will also not meet Canadian bilingual labelling requirements. We review your existing formulation and label against Canadian standards and identify exactly what needs to change.

How long does a DIN application take to approve?

Health Canada targets approximately 90 days for monograph-aligned applications. Non-monograph submissions require more extensive supporting evidence and can take meaningfully longer. We confirm which pathway you're actually on before submission so your timeline expectations are realistic from day one.

What happens if I sell an OTC drug in Canada without a DIN?

It isn't permitted. Health Canada uses the DIN system to track every approved drug product, and selling without one exposes your company to enforcement action, including product seizure and removal from sale.

Is my product an OTC drug, an NHP, or a cosmetic?

This depends on your ingredients, claims, and intended use — and the line isn't always obvious. For example, mineral-based sunscreens generally follow Canada's NHP licensing process, while chemical-filter sunscreens follow the drug submission pathway. Misclassifying your product leads directly to a rejected or delayed submission. We confirm the correct category before you commit to a pathway.

Need clarity on your OTC regulatory pathway?

Book a confidential strategy call to confirm classification, monograph alignment, labelling requirements, and your fastest compliant path to market.